Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

Both sacubitril/valsartan (Entresto) and enalapril (Vasotec) were associated with improvement in clinical measures among children aged 1 month to younger than 18 years who had heart failure ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

USV Pvt. Ltd. has introduced OnArni, a fixed dose combination of Sacubitril and Valsartan, for the management of Heart ...

Indian Biotechnology firm Biocon has received approval of its ANDA for Sacubitril/Valsartan Tablets from the US Food and Drug ...

sacubitril); do not administer benazepril/HCT within 36hrs of switching to or from sacubitril/valsartan. Concomitant aliskiren in patients with diabetes. Fetal toxicity may develop; discontinue if ...